Replication competent HIV-1 viruses that express intragenomic microRNA reveal discrete RNA-interference mechanisms that affect viral replication by Klase, Zachary et al.
RESEARCH Open Access
Replication competent HIV-1 viruses that express
intragenomic microRNA reveal discrete RNA-
interference mechanisms that affect viral
replication
Zachary Klase, Laurent Houzet and Kuan-Teh Jeang
*
Abstract
Background: It remains unclear whether retroviruses can encode and express an intragenomic microRNA (miRNA).
Some have suggested that processing by the Drosha and Dicer enzymes might preclude the viability of a
replicating retroviral RNA genome that contains a cis-embedded miRNA. To date, while many studies have shown
that lentiviral vectors containing miRNAs can transduce mammalian cells and express the inserted miRNA
efficiently, no study has examined the impact on the replication of a lentivirus such as HIV-1 after the deliberate
intragenomic insertion of a bona fide miRNA.
Results: We have constructed several HIV-1 molecular clones, each containing a discrete cellular miRNA positioned
in Nef. These retroviral genomes express the inserted miRNA and are generally replication competent in T-cells. The
inserted intragenomic miRNA was observed to elicit two different consequences for HIV-1 replication. First, the
expression of miRNAs with predicted target sequences in the HIV-1 genome was found to reduce viral replication.
Second, in one case, where an inserted miRNA was unusually well-processed by Drosha, this processing event
inhibited viral replication.
Conclusion: This is the first study to examine in detail the replication competence of HIV-1 genomes that express
cis-embedded miRNAs. The results indicate that a replication competent retroviral genome is not precluded from
encoding and expressing a viral miRNA.
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Background
RNA interference (RNAi) is a regulatory mechanism
conserved in organisms from protozoans to mammals
[1-3]. This process employs a small single stranded
RNA of 20-24 nucleotides in length which is used as a
guide-RNA to direct an RNA-induced silencing complex
(RISC) containing the argonaut protein and co-factors
to the targeted RNA [4-8]. Human cells encode 1,527
miRNA genes [9] that are transcribed into precursor
primary miRNAs (pri-miRNAs) which are processed in
the nucleus by Drosha into shorter hairpin products
called pre-miRNA. The pre-miRNAs are exported into
the cytoplasm by Exportin-5, and cleaved by Dicer to
generate 20-24 nucleotide RNA duplexes, one strand of
which is loaded into the Argonaute containing RISC
[10-14]. miRNA-RISC complexes can silence target
mRNAs via imperfect complementarity with sequences
located in the 5’-UTR [15-17], coding sequences [18,19],
and most commonly the 3’-UTR [2,20,21].
The RNAi pathway is pleotropically functional in
many diverse biological processes; and its dysregulation
leads to a plethora of pathologies including cancers,
metabolic disorders, and infectious diseases [22-24]. In
plants, RNAi as a host defense against viral infections
has been well-established [25-27]. In vetebrates, the effi-
cacy of RNAi based antiviral defense is debated [28-32],
although several findings support the importance of this
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evidence that RNAi is employed by cells as a mean to
keep mammalian endogenous retroviruses (i.e. retrotran-
sposons) under check [41-46].
Several studies have reported that cellular miRNAs can
modulate HIV-1 replication in human cells. For example,
it was found that miR-28, miR-125b, miR-150, miR-223
and miR-382 function to induce HIV-1 latency in T-cells
[47], and that these same miRNAs conferred resistance to
HIV-1 infection in blood monocytes [48]. Furthermore,
miR-29 has been shown to silence HIV-1 mRNAs that
contain Nef sequences [49-51]. Finally, there is accumulat-
ing evidence that some cellular miRNAs may indirectly
affect HIV-1 through the regulation of cellular proteins,
such as Cyclin T1 and PCAF, which are employed for viral
replication [52,53]. These findings are underscored by stu-
dies demonstrating, in models of spreading infection, that
the over-expression of proteins involved in RNAi
decreases viral replication while the knock-down of these
proteins increases viral replication [52,54-56]
Relevant to their interaction with host cells is the ques-
tion whether retroviruses can encode viral miRNAs.
Some have suggested that the potential vulnerability of
RNA-genomes to processing by RNAse III enzymes such
as Drosha and Dicer might preclude RNA-viruses from
containing cis-embedded miRNAs [37,57-59]. However,
it has been shown that the infecting retroviral genome is
apparently shielded by RNA-binding proteins rendering
it inaccessible to targeting by RNAi factors [60]. Thus, it
remains an open question whether a replication compe-
tent retroviral genome can encode a viral miRNA. Rele-
vant to this issue, multiple laboratories have reported the
processing of the viral TAR RNA into a miRNA-like
non-coding RNA in HIV-1 infected cells [61-65]. The
complexity of this multitude of findings cautions that a
full understanding of the functions of HIV-1 associated
non-coding RNAs awaits further investigation [64].
The current study was undertaken to answer more
clearly whether an HIV-1 genome encoding an intrage-
nomic miRNA is precluded from replication competence.
We approached this question by creating several HIV-1
molecular genomes that contain discrete cellular miRNAs
positioned in the Nef gene. We asked whether the intrage-
nomic presence of the inserted miRNA in HIV-1 prevents
viral replication in human cells. Our results showed no
absolute preclusion in human cells against the replication
of an HIV-1 genome expressing an intragenomic miRNA.
Results
Construction of five discrete HIV-1 molecular clones
containing intragenomic miRNA
We began our study by individually cloning five cellular
miRNAs separately into the Nef locus of the NL4-3
molecular clone (Figure 1A) [66]. This locus was chosen
because it is well-established that the HIV-1 Nef gene is
dispensible for viral replication in cultured human cells
[66,67] The five cellular miRNAs, miR28, miR29b,
miR138, miR211, and miR326, were selected because
each potentially has a complementary target sequence in
the HIV-1 genome (Figure 1A). Figure 1A illustrates the
imperfect complementarities, with the respective calcu-
lated free energies for duplex formation, between the
v a r i o u sm i R N A sa n dt h e i rp u t a t i v eH I V - 1t a r g e t
sequences. For comparison purposes, several cellular
miRNA - mRNA pairs with similarly imperfect comple-
mentarities that have been reported in the literature are
s h o w ni nF i g u r e1 B [ 6 8 - 7 0 ] .W ea l s oc l o n e dt w oa d d i -
tional miRNAs, let7a and miR329, into HIV-1 NL4-3.
Based on target site prediction, these two miRNAs have
no target sequence complementarities in the HIV NL4-3
genome. A final clone was created to incorporate a
scrambled version of the let7a sequence. This sequence,
designated as let7 scr, cannot fold into an RNA hairpin
and is not expected to be processed into a miRNA (Fig-
u r e1 C ) .A l lt h ec h i m e r i cN L 4 - 3 - m i R N Ag e n o m e sw e r e
checked by restriction digestion to verify a correctly-
sized insert (Figure 2), and each clone was directly
sequenced to confirm the expected identity.
Expression of the inserted miRNA from the chimeric NL4-
3 miR molecular clones
We evaluated the expression of the inserted miRNAs
from the NL4-3-miRNA clones. 293T cells were trans-
fected individually with two micrograms of pNL4-3 let7
scr, pNL4-3 let7a, pNL4-3 miR28, pNL4-3 miR29b,
pNL4-3 miR138, pNL4-3 miR211, pNL4-3 miR326, or
pNL4-3 miR329. Forty-eight hours after transfection,
RNA was extracted from the cells, and miRNA levels
were quantified using the QuantiMiR qPCR kit (Systems
Biosciences). The copy numbers per cell of let7a, miR28,
miR29b, miR138, miR211, miR326 and miR329 were
determined based on 10 pg of RNA per cell (Figure 3).
We found that the transfection of pNL4-3 miR28,
pNL4-3 miR29b, pNL4-3 miR138, pNL4-3 miR326 and
pNL4-3 miR329 increased the expression of the corre-
sponding miRNAs by 142, 169, 1134, 236 and 124
copies per cell, respectively. The basal level of miR326
in 293T cells is relatively high at 297 copies per cell;
however, the transfection of pNL4-3 miR326 into the
cells further increased this amount by 236 copies. The
transfection of pNL4-3 miR28 and pNL4-3 miR29b
increased the expression of the corresponding miRNAs
by 142 and 169 copies, respectively. The transfection of
pNL4-3 miR211 increased miR211 copy number by
11,597 per cell (a greater than 100 fold increase). The
transfection of pNL4-3 let7a produced the smallest
increase in copy number adding only 40 additional
copies per cell. Despite individual variabilities, the
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HIV-1 Nef are expressed on the order of 10
2 copies or
more per cell, with the exception of miR211 which is
expressed at a considerably higher level.
Intragenomic expression of miR28, miR211 and miR326
reduced single cycle HIV-1 infectivity
We next determined if expression of the intragenomic
miRNA influences HIV-1 replication. We examined the
number of infectious HIV-1 virions produced from trans-
fection into cells of the respective NL4-3-miRNA gen-
omes. Accordingly, 293T cells were transfected
individually with two micrograms of pNL4-3 let7 scr,
pNL4-3 let7a, pNL4-3 miR28, pNL4-3 miR29b, pNL4-3
miR138, pNL4-3 miR211, pNL4-3 miR326 or pNL4-3
miR329. Forty-eight hours after transfection, supernatants
were harvested, assayed for reverse transcriptase activity,
and equal RT-amounts were used to infect TZMbl indica-
tor cells [71]. Twenty-four hours after infection, the
TZMbl cells were fixed, and the infectivity of the respec-
tive samples was determined by b-galactosidase assay. The
relative infectivity of each sample was measured by count-
ing the number of blue cells and comparing the value rela-
tive to the number produced from infection with the NL4-
3 let7 scr virus (Figure 4). Compared to the NL4-3 let7 scr
control, no significant difference was seen for the NL4-3
let7a, NL4-3 miR329, NL4-3 miR29b, and NL4-3 miR183
viruses; however, viruses expressing miR28, miR211 and
miR326 showed a statistically significant reduction in
infectivity (by 49%, 20% and 57%, respectively). The
absence of significantly down-regulated replication for the
miR29b expressing virus is puzzling because miR29b has
miR28  ѐG = -23.3 
miR29b  ѐG = -29.8 
miR138     ѐG = -17.2 
miR211  ѐG = -19.4 
miR326  ѐG = -24.2 
A) 
B) 
C. elegans Let7 to lin41 site 1  ѐG = -27.2 
C. elegans Let7 to lin41 site 2  ѐG = -27.8 
D. Melanogaster miR10 to Scr  ѐG = -26.0 
C) 
let7a  UGGGAUGAGGUAGUAGGUUGUAUAGUUUUAGGGUCACACCCACCACUGGGAGAUAACUAUACAAUCUACUGUCUUUCCUA
miR329  GGUACCUGAAGAGAGGUUUUCUGGGUUUCUGUUUCUUUAAUGAGGACGAAACACACCUGGUUAACCUCUUUUCCAGUAUC
let7 scr  GTTGTTTAGTATAGTTCTATTGCCCCAACTACGGCTAATAAGGTATCGTCCGAAGGTAGTCCTCAATTGAGGATACGGAT
Figure 1 Sequences of miRNAs and their predicted RNA targets. (A) The putative target sites (with indicated ΔGs) for miR28, miR29b,
miR138, miR211 and miR326 in the HIV-1 genome are shown. The miRNA sequence is listed at the top, with the seed sequence underlined; the
HIV-1 target sequence is listed at the bottom in the 5’ to 3’ orientation. The numbers indicate the target position in the HIV NDK proviral
genome. B) Three examples of published miRNA-mRNA target pairs (with ΔG values) with indicated mismatches or G:U pairings in the seed
sequence. C) The primary miRNA sequences of let7a, miR329 and let7 scr which were inserted into the pNL4-3 proviral plasmid.
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expression [49,50]. It is possible that different levels of
miRNA expression and/or cell type or cell culturing differ-
ences account for the divergent experimental results.
Reduced infectivity of NL4-3 miR211 and NL4-3 miR326
arises from different mechanisms
The NL4-3 miR21, the NL4-3 miR326 and the NL4-3
miR28 viruses displayed reduced infectivity. We noted
that the NL4-3 miR211 virus expressed its correspond-
ing miRNA at a much higher level (>11,000 copies of
miR211 per cell) than the NL4-3 miR326 virus (Figure
3). It is possible that an overly efficient processing of a
cis-embedded miRNA within a viral RNA genome may
deleteriously affect viral replication. Potentially, the
reduced replication of the NL4-3 miR211 virus may be
explained by this mechanism. By contrast the reduced
replication of the NL4-3 miR326 virus may be because
M  1  2  3  4  5  6  7  8  9  10 
Inserted miRNA: 
let7 scram 
let7a 
miR28 
miR29b 
miR138 
miR211 
miR326 
miR329 
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Figure 2 Cloning of cellular miRNA sequences into NL4-3. Schematic representation (Top) of the NL4-3 genome showing the insertion of
the miRNA sequences into the Nef locus. The bottom panel shows PCR analyses of the indicated molecular clones performed to verify insertion.
The p398.6 clone was a shuttle vector used in transferring the cloned miRNA into the pNL4-3 full length molecular clone. PCR primers were
selected that flank the insertion site in Nef. Wild-type virus (lane 1) yielded a band of 220 bp. The p398.6 shuttle vector (lane 2) yielded a band
of 143 bp. Insertion of the miRNA sequences (lanes 3-10) yielded a PCR fragment size commensurate with the size of the insert. Sizes of the
molecular weight ladder (M) are indicated on the left.
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its complementary NL4-3 target sequence (Figure 1A).
To investigate the above possibilities, we employed
synthetic miRNA-mimics or anti-miRNAs (antagomir)
to effect or obstruct miRNA-mediated silencing.
Thus, 293T cells were transfected with pNL4-3 let7
scr molecular clone with or without 100 pM synthetic
miR326-mimic; and separately 293T cells were trans-
fected with pNL4-3 miR326 with or without 100 pM
synthetic anti-miR326 antagomir. Cell culture super-
natants were harvested from these transfections, fil-
tered, and measured for infectious units via infection
of TZMbl cells (Figure 5A). We observed that trans-
fected pNL4-3 let7 scr in the setting of transfected
synthetic miR326, but not control miRNA mimic,
produced a lowered viral infectivity. By contrast,
pNL4-3 miR326 in the setting of synthetic miR326
antagomir showed an increased infectivity. These
results are compatible with the interpretation that the
reduction of NL4-3 miR326 replication is explained
likely by miR326-mediated silencing of a complemen-
tary viral RNA target sequence.
We performed a similar analysis using the NL4-3
miR211 virus. In these experiments, 293T cells were
transfected with pNL4-3 let7 scr with or without 100
pM of synthetic miR211, and pNL4-3 miR211 was sepa-
rately transfected into 293T cells with or without 100
pM anti-miR211 antagomir. Next, cell culture superna-
tants were harvested and measured for infectivity using
TZMbl cells (Figure 5B). Interestingly, the production of
the NL4-3 let7 scr virus was not silenced by co-trans-
fected synthetic miR211; nor was the infectivity of NL4-
3 miR211 virus increased by co-transfected synthetic
anti-miR211 antagomirs. These results suggest that the
observed reduction in replication of the NL4-3 miR211
virus is unlikely due to miR211-mediated silencing of a
putative complementary HIV-1 RNA target sequence
(Figure 1A). Further experiments are needed to deter-
mine whether the predicted miR211 complementary
viral sequence (Figure 1A) is not a competent target or
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Figure 3 NL4-3 miR viruses express miRNA in human cells. 293T cells were seeded in a 6-well plate and transfected with 2 μg pNL4-3 let7
scr, pNL4-3 let7a, pNL4-3 miR28, pNL4-3 miR29b, pNL4-3 miR138, pNL4-3 miR211, pNL4-3 miR326 and pNL4-3 miR329. RNA was extracted at 48
hours post transfection and used to determine miRNA levels using qPCR. Copy number per cell was determined based on normalization to
miR16 and the assumption of 10 pg of RNA per cell. Each graph shows the expression of a specific miRNA after transfection of the indicated
chimeric NL4-3 molecular clone. * indicates a p-value < 0.05 and ** indicates a p-value < 0.01.
Klase et al. Cell & Bioscience 2011, 1:38
http://www.cellandbioscience.com/content/1/1/38
Page 5 of 13if synthetic miR211 is not efficiently employed as a
guide RNA by RISC.
The Drosha and Dicer proteins act sequentially inside
the cell to process a precursor miRNA into a mature
miRNA. It has been found that the knockdown of either
protein affects the production of mature miRNAs. To
ask if either Drosha or Dicer contributes to the reduced
infectivity of the NL4-3 miR211 virus, we transfected
293T cells separately with siRNA against Dicer, Drosha,
or EGFP, as a control. Twenty-four hours after the
siRNA transfection, the cells were transfected with
pNL4-3 let7 scr, pNL4-3 miR211, or pNL4-3 miR326.
Forty-eight hours after the second transfection, cell cul-
ture supernatants were harvested, filtered and used to
determine the number of infectious units using TZMbl
cells (Figure 6A). The successful knockdown of Dicer or
Drosha mRNA by the transfected siRNAs was confirmed
by quantitative RT-PCR analyses of RNAs extracted
from the indicated 293T cells (Figure 6B). We observed
that neither the knockdown of Dicer nor Drosha pro-
duced appreciable effects on the infectivity of the NL4-3
let7 scr virus. Interestingly, the knockdown of Drosha
increased the infectivity of the NL4-3 miR211 virus,
while the knockdown of Dicer did not (Figure 6A, com-
pare bar 4 to 5 and 6). In contrast, knockdown of either
Dicer or Drosha increased the infectivity of NL4-3
miR326 (Figure 6A, compare bar 7 to 8 and 9). These
results are compatible with the interpretation that the
reduced replication of the NL4-3 miR211 virus may be
due to overly robust nuclear processing by Drosha of
viral mRNAs transcribed from the integrated pNL4-3
miR211 provirus. Indeed, qPCR analysis of the cell asso-
ciated viral RNA confirmed a significant reduction of
full-length viral RNA in the pNL4-3 miR211 transfected
cells compared to pNL4-3 let7a or pNL4-3 miR326
transfected cells (Additional file 1). Because both Drosha
and Dicer knockdowns are expected to reduce the pro-
duction of mature miR326, the observed increase in the
replication of the NL4-3 miR326 virus is consistent with
a reduction of miR326-mediated mRNA silencing of this
virus.
Chimeric NL4-3 miR viruses produce a spreading viral
infection in cultured cells
Next, we asked if chimeric NL4-3 miRNA viruses that
express the inserted intragenomic miRNA support a
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Figure 4 Analyses of viral stocks generated from transfection in 293T cells. 293T cells were seeded in a 6-well plate and transfected with 2
μg pNL4-3 let7 scr, pNL4-3 let7a, pNL4-3 miR28, pNL4-3 miR29b, pNL4-3 miR138, pNL4-3 miR211, pNL4-3 miR326 and pNL4-3 miR329.
Supernatants were harvested at 48 hours post transfection and filtered to remove any contaminating cells. Supernatants were used to infect the
HeLa derived TZMbl reporter cell line and to determine reverse transcriptase (RT) activity. Twenty-four hours after infection, the TZMBl cells were
fixed and infected cells were visualized by b-galactosidase staining. Infectious units (IU)/RT were determined and graphed relative to NL4-3 let7
scr control. Data shown are the averages of three replicates. ** indicates a p-value < 0.01 and *** indicates a p-value < 0.001 compared to
control.
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Page 6 of 13spreading virus infection in cultured human cells. To
answer this question, we generated stocks of NL4-3,
NL4-3 let7 scr, NL4-3 let7a, NL4-3 miR211, and NL4-3
miR326 viruses to separately infect Jurkat T-cells (Figure
7). Wild-type NL4-3 virus, NL4-3 let7 scr virus, and
NL4-3 let7a virus, all replicated in a spreading manner
very similarly. By comparison, the NL4-3 miR326 virus
also produced a spreading infection, albeit with a 50%
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Figure 5 Analyses of the trans expression of miRNAs and antagomirs on the infectivity of the indicated NL4-3 viruses. 293T cells were
seeded in a 6-well plate and transfected with 2 μg of proviral plasmid and 100 pM of the indicated RNA. Supernatants were harvested at 24
hours post transfection, filtered and used to determine infectious units as normalized by RT activity. (A) Evaluation of NL4-3 miR326 virus. NL4-3
let7 scr was co-transfected with either control RNA (column 1) or miR326 (column 2). NL4-3 miR326 was co-transfected with either control RNA
(column 3) or an anti-miR326 antagomir (column 4). Results are shown relative to the control NL4-3 let7 scr virus. (B) Evaluation of NL4-3 miR211
virus. NL4-3 let7 scr was co-transfected with either control RNA (column 1) or miR211 (column 2). NL4-3 miR211 was co-transfected with either
control RNA (column 3) or an anti-miR211 antagomir (column 4). Results are shown relative to the control NL4-3 let7 scr virus. All data are the
averages of three replicates. ** indicates a p-value < 0.01.
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Interestingly, the NL4-3 miR211 virus was incompetent
in promoting a spreading infection. These results indi-
cate that the expression of an intragenomic miRNA
within a retrovirus genome does not absolutely preclude
replication competence. However, some miRNAs, like
miR211, may be unusually good substrates for Drosha
cleavage of the cis-inserted miRNA sequences resulting
in an adverse outcome on virus replication. (Figure 8).
Discussion
The ability of mammalian DNA viruses to encode viral
miRNAs is well accepted. By contrast, it remains
debated whether RNA viruses or retroviruses can
encode and express viral miRNAs and remain replica-
tion competent. The current study tested the hypothesis
that an HIV-1 genome with a cis-embedded miRNA can
express the miRNA and propagate a spreading infection
in cultured T cells.
To check this hypothesis, we constructed several chi-
meric HIV-1-miRNA molecular genomes with discrete
cellular miRNAs cassetted into the viral Nef gene (Fig-
ure 2). For most of these chimeric genomes (NL4-3
miR28, NL4-3 miR29b, NL4-3 miR138, NL4-3 miR326
and NL4-3 miR329), the expression of the Nef-inserted
miRNAs was several hundred copies per cell (Figure 3).
One of the chimeric HIV-1 miRNA virus, NL4-3
miR211, had an unusually high level (>11,000 copies) of
miRNA expression (Figure 3). When the viruses were
tested for viral infectivity, three (NL4-3 miR28, NL4-3
miR211, and NL4-3 miR326) showed significantly
reduced infectivity when compared to the NL4-3 let 7
scr and NL4-3 let7a control viruses (Figure 4).
The NL4-3 miR211 and NL4-3 miR326 viruses were
studied in greater detail to understand the reason(s) for
reduced infectivity. We explored two possible explana-
tions. One possibility was that the expressed intrage-
nomic miR211 or miR326 miRNAs recognize a cis-HIV-
1 target sequence (Figure 1A) and that this miRNA-viral
RNA interaction resulted in silencing, reducing viral
infectivity. This explanation could be confirmed if an
antagomir targeted against either miR211 or the miR326
would rescue the infectivity of the respective NL4-3
miR211 or pNL4-3 miR326 virus. That the infectivity of
NL4-3 miR326, but not NL4-3 miR211, was rescued by
a sequence-specific antagomir (Figure 5A) supported the
interpretation that miRNA-viral RNA silencing explains
the reduced infectivity of the former, but not the latter,
virus.
What might explain the reduced infectivity of the
NL4-3 miR211 virus? A second possibility is that the
decreased infectivity may be due to unusually high effi-
ciency of processing miR211 from NL4-3 transcripts
that contain cis-inserted miR211 sequence. It may be
that some miRNAs are simply better than other miR-
NAs as substrates for Drosha, Dicer, or both. If all viral
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Figure 6 The effect of Dicer and Drosha knockdown on NL4-3 miR326 and NL4-3 miR211 viruses. 293T cells were seeded in a 6-well
plate and transfected with 10 pM siRNA against EGFP (control), Dicer, or Drosha. Twenty-four hours post RNA transfection, the cells were
transfected with 2 μg of pNL4-3 let7 scr, pNL4-3 miR326 or pNL4-3 miR211. (A) Supernatants were harvested 48 hours post viral transfection and
used to determine infectious units as normalized to equal RT values. (B) Total RNA was extracted from transfected 293T cells and used to
determine relative expression of Dicer (top panel) and Drosha (lower panel) by quantitative qPCR. Amounts were normalized to GAPDH. Data are
shown relative to control (siEGFP) transfection with each virus and are the averages of three replicates. * indicates a p-value < 0.05 and **
indicates a p-value < 0.01.
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Drosha or Dicer or both, then such events would
severely hamper viral protein expression and could
explain the severely attenuated infectivity of the NL4-3
miR211 virus. Indeed, we noted that the knockout of
Drosha, but not Dicer, rescued NL4-3 miR211 infectivity
(Figure 6A) while either knock down improved the
infectivity of the NL4-3 miR326 virus (Figure 6A).
Taken together with the findings in Figure 5, the results
support that two different mechanisms are operative in
reducing NL4-3 miR326 and NL4-3 miR211 viral repli-
cation (Figure 8).
Our NL4-3 miR211 virus results agree with a similar
observation made by Liu et al.i nt h e i rs t u d yo fm i R N A
expression using a single round lentiviral gene delivery
vector [57]. Liu et al. also found that the processing by
Drosha of some miRNA-cassettes in lentivectors was
one of several mechanisms that reduced particle titers.
Because Drosha processing is a nuclear event, the likely
scenario for reduced NL4-3 miR211 infectivity is the
overly robust cleavage of miR211-embedded HIV-1
RNAs transcribed from the integrated proviral DNA
genome (Figure 8), not from the cytoplasmic cleavage of
miR211-embedded HIV-1 RNA genome. This interpre-
tation agrees with the earlier observation made by
Berkhout and colleagues that the infecting lentiviral
RNA genome is well-protected from RNAi-mediated
silencing [60].
Finally, we observed that the NL4-3 let7a and the
NL4-3 miR326 viruses are capable of a spreading infec-
tion in cultured Jurkat T-cells. These results are consis-
tent with no absolute preclusion against a replicating
retrovirus encoding and expressing an intragenomic
miRNA. Previously, it has been suggested that the pro-
clivity of DNA viruses to replicate in the nucleus and
RNA viruses to replicate mostly in the cytoplasm might
explain why the former and latter have varying capacity
for encoding viral miRNAs. Since a large part of the ret-
roviral life cycle takes place in the nucleus and the
genomic retroviral RNA in the cytoplasm is shielded by
RNA-binding proteins [60], these processes may explain
w h ys o m er e t r o v i r u s e sl i k eH I V - 1d op r o d u c em o d e s t
levels of processed non-coding viral RNAs [61,63,64].
Other retroviruses like BLV are suggested to potentially
encode more non-coding viral RNAs [72]. A recent
s t u d yr e p o r t st h ee x p r e s s i o no fam i R N A - l i k es m a l l
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Page 9 of 13RNA from the highly structured 3’ UTR of West Nile
Virus and found that this RNA is supportive of viral
replication [73]. If true, this report would represent
another example of a miRNA or miRNA-like RNA
encoded by an RNA virus. These reports, together with
our currently demonstrated replication competence of
HIV-1 genomes expressing inserted cellular miRNAs,
encourage additional investigation into the nuanced
miRNA-encoding capabilities of DNA viruses, RNA
viruses, and retroviruses.
Methods
Cell culture
293T and TZMbl cells were maintained in DMEM sup-
plemented with L-glutamine, Penicillin/Streptomycin
and 10% fetal bovine serum. For transfections, cells were
split 24 hours prior to transfection into 6-well plates at
500,000 cells/well. Cells were transfected with lipofecta-
mine LTX (Invitrogen) according to manufacturer’s
instructions. For production of viral stocks, the superna-
tant was harvested at 48 hours after transfection. For
siRNA transfections, the cells were first transfected with
siRNAs and then re-transfected 24 hours later with
proviral plasmids. Jurkat T-cell line was maintained in
RPMI supplemented with L-glutamine, Penicillin/Strep-
tomycin and 10% fetal bovine serum.
RNA isolation, qRT-PCR and miRNA measurement
RNA was extracted using Trizol reagent (Invitrogen) fol-
lowing manufacturer’s protocol. For the determination of
mRNA levels, 1 microgram of RNA was used to create
cDNA using the SuperScript III First-Strand Synthesis kit
(Invitrogen). Following reverse transcription, the samples
were diluted 1:50, and 2.5 microliters were used for
quantitative PCR in a BioRad CFX96 or CFX384 qPCR
machine. All mRNA analyses were normalized to
GAPDH. Nucleic acid amplification was tracked by SYBR
Green method. For miRNA quantitation, 1 microgram of
RNA was processed using QuantiMir (Systems
Bioscience Inc.); the resulting tagged cDNA was quanti-
fied using miRNA specific primers via qPCR. All miRNA
analyses were normalized to the cellular miRNA miR16.
Infections, RT and TZMbl assay
For infection of Jurkat cells, 6 × 10
6 cells were seeded in
2 ml of media and exposed to the indicated dose of
Drosha-cleavage mediated viral attenuation  RISC mediated RNA silencing 
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Cytoplasm 
RISC 
miR-326 
Transcription Transcription 
Nucleus 
HIV mRNA  HIV mRNA 
HIV provirus  HIV provirus 
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A) B ) 
Drosha 
premiRNA 
Dicer 
Figure 8 Two mechanisms by which expressed intragenomic miRNAs can affect viral replication. (A) A ni n t e g r a t e dH I V - 1g e n o m ei s
transcribed into viral mRNAs containing the embedded primary miRNA. This viral mRNA with an embedded primary miRNA may be recognized
and cleaved in the nucleus by Drosha (in yellow). If Drosha-mediated cleavage is overly efficient, few uncleaved viral RNA would be left available
to export into the cytoplasm for translation and/or packaging. This would then result in attenuated or incompetent viral replication like the NL4-
3 miR211 virus. (B) For most chimeric NL4-3 miRNA viruses, Drosha processing of the embedded primary miRNA is relatively inefficient. Thus two
pools of RNAs (unprocessed viral RNA and processed pre-miRNAs) are exported from the nucleus into the cytoplasm. In the case of the NL4-3
miR326 virus, the primary miR326 is further processed by Dicer into mature miR326 which associates with RISC and silences complementary viral
target sequence leading to the attenuation of viral replication.
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Page 10 of 13virus supernatant for 24 hours. Cells were then washed
and seeded in 10 ml of fresh RPMI, and sampled over
time. Replication was measured through use of the RT
activity assay: 5 μl of supernatant were added to 50 μlo f
RT reaction cocktail (60 mM TrisHCl, 75 mM KCl, 5
mM MgCl2, 1.04 mM EDTA, 0.1 NP-40, 5 μg/ml polyA
and 0.16 μg/ml oligo dT) and incubated for two hours
at 37°C. The reaction mix was spotted on DEAE mem-
brane, washed with SSC, and dried before counting. For
TZMbl assay, cells were seeded in a 96 well plate at
15,000 cells/well for 24 hours. Medium was then
replaced with fresh RPMI containing serial dilutions of
viral supernatant. Twenty-four hours post infection, the
cells were washed, fixed and assayed for the presence of
b-galactosidase by X-gal enzymatic assay. Blue cells
were counted, and the number of infectious units per
volume was computed based on the dilution of infecting
supernatant.
Sequencing
Cellular DNA from Jurkat T-cells at 8 days post infec-
tion was extracted using Qiagen DNA easy kit. PCR for
insertion sites was performed, and the resulting frag-
ments were gel purified and cloned into Invitrogen’s
TopoTA cloning vector before being directly sequenced.
Cloning
For cloning for miRNA into NL4-3, we followed a pre-
viously described procedure [66]. In brief, the sequence
of each pre-miRNA was determined by consulting the
miRBase for the human miRNA [74,75]. PCR primers
were designed to amplify these sequences with the addi-
tion of SalI( 5 ’ end) and XhoI( 3 ’ end) to each pre-
miRNA. PCR products were cloned into TopoTA vector
(Invitrogen) and excised with SalI and XhoI. Pre-miRNA
fragments were then inserted into the XhoIs i t eo fa
ΔNef shuttle vector, screened for orientation and then
moved into the full length pNL4-3 proviral vector to
produce the NL4-3 miR clones. All clones were
sequenced to verify the proper insertion of the pre-
miRNA sequence.
Primers and oligonucleotides for cloning
Primers for generation of SalI/XhoI miRNA precursors -
let7a ATCGTCGACTGGGATGAGGTAGTAGGTTG-
TATAG/ACTCGAGTAGGAAAGACAGTAGATTGTA-
TAG, miR28 ATCGTCGACGGTCCTTGCCCTCAA
GGAGCTCACA/ACTCGAGAGTGCCTGCCCTCCAG-
GAGCTCACA, miR29b ATCGTCGACCUUCAG-
GAAGCUGGUUUCAUAUGGU/ACTCGAGCCCC-
CAAGAACACTGATTTCAAATG, miR138 ATCGTC
GACCCCTGGCATGGTGTGGTGGGGCAGC/ACTC-
GAGCCTGTAGTGTGGTGTGGCCCTGGTG, miR211
ATCGTCGACUCACCUGGCCAUGUGACUUGUGG
GC/ACTCGAGCTCCGTGCTGTGGGAAGTGA-
CAACT, miR326 ATCGTCGACCTCATCTGTCTGTT
GGGCTG/ACTCGAGTGAATCCGCCTCGGGGCTGG,
miR329 ATCGTCGACGGTACCTGAAGAGAGGTT
TTCTGGG/ACTCGAGGATACTGGAAAAGAGGTTA
ACCAGG
Oligonucleotides for the generation of let7 scr through
annealing - ATCGTCGACGTTGTTTAGTATAGTT
CTATTGCCCCAACTACGGCTAATAAGGTATCG
TCC
GAAGGTAGTCCTCAATTGAGGATACGGATCTC-
GAGGCC, GGCCTCGAGATCCGTATCCTCAATT-
GAGGACTACCTTCGGACGATACCTTATTAGCC
GTA
GTTGGGGCAATAGAACTATACTAAACAACGT
CGACGAT
Additional material
Additional file 1: Increased processing of viral genome-length RNAs
in pNL4-3 miR211 transfected cells. 293T cells were seeded in a 6-well
plate and transfected with 2 μg pNL4-3 let7a, pNL4-3 miR211, or pNL4-3.
Total RNA was extracted from the cells at 48 hours post transfection.
RNA was treated with DNase, and cDNA was made by reverse
transcriptase reaction using either poly dT (dT) or random hexamer
(hexamer) as a primer. qPCR was performed on the cDNA to measure
the presence of Gag RNA. In this assay, poly dT is anticipated to quantify
genome-length Gag RNAs, while random hexamer will identify all
genome-length as well as subgenome-length Gag RNAs. Quantities were
normalized by GAPDH and shown relative to pNL4-3 let7a. * indicates a
p-value < 0.01, ** indicates a p-value < 0.01, and *** indicates a p-value
<0.001 as compared to NL4-3 let7a.
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